Skip to main content

Are you a legal professional? Visit our professional site

Please enter a legal issue and/or a location
Begin typing to search, use arrow keys to navigate, use enter to select

FDA Rejects Potential Vioxx Successor

By Admin on April 27, 2007 12:21 PM

Pharmaceutical manufacturer Merck & Co., Inc. announced that it has received a "non-approvable letter" from the U.S. Food and Drug Administration (FDA) in response to Merck's efforts to market its painkiller Arcoxia in the U.S. An anti-inflammatory drug called a "Cox-2 inhibitor", Arcoxia was seen as a potential successor to Merck's Vioxx, another Cox-2 inhibitor which was withdrawn from the marketplace in September of 2004 after it was linked to increased risk of heart attack and stroke. Arcoxia will continue to be available outside of the U.S., according to Merck.

You Don’t Have To Solve This on Your Own – Get a Lawyer’s Help

Meeting with a lawyer can help you understand your options and how to best protect your rights. Visit our attorney directory to find a lawyer near you who can help.

Or contact an attorney near you:
Copied to clipboard

Find a Lawyer

More Options